Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $47.00.

RAPP has been the topic of several analyst reports. Citizens Jmp lifted their price target on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. BTIG Research restated a “buy” rating and set a $47.00 target price on shares of Rapport Therapeutics in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. HC Wainwright raised their price target on Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Wall Street Zen downgraded Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th.

Insider Activity at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 5,083 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $26.11, for a total value of $132,717.13. Following the transaction, the chief executive officer owned 25,812 shares of the company’s stock, valued at approximately $673,951.32. The trade was a 16.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Krishnaswamy Yeleswaram sold 2,840 shares of the company’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $30.05, for a total transaction of $85,342.00. Following the transaction, the insider owned 296,991 shares of the company’s stock, valued at approximately $8,924,579.55. This represents a 0.95% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 67,655 shares of company stock valued at $1,863,705. 13.57% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Affinity Asset Advisors LLC bought a new stake in Rapport Therapeutics in the second quarter worth $2,270,000. TD Asset Management Inc lifted its position in Rapport Therapeutics by 20.9% during the second quarter. TD Asset Management Inc now owns 196,870 shares of the company’s stock valued at $2,238,000 after purchasing an additional 34,052 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Rapport Therapeutics in the 2nd quarter worth $130,000. Tudor Investment Corp ET AL bought a new stake in shares of Rapport Therapeutics in the 3rd quarter worth about $331,000. Finally, Maven Securities LTD bought a new stake in shares of Rapport Therapeutics in the 3rd quarter worth about $594,000.

Rapport Therapeutics Stock Up 1.2%

NASDAQ RAPP opened at $27.97 on Friday. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $42.27. The company has a market capitalization of $1.33 billion, a P/E ratio of -10.32 and a beta of 1.63. The stock’s 50-day moving average price is $28.38 and its 200-day moving average price is $24.89.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.